Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid screening of IgG quality attributes - effects on Fc receptor binding.
Geuijen KPM, Oppers-Tiemissen C, Egging DF, Simons PJ, Boon L, Schasfoort RBM, Eppink MHM. Geuijen KPM, et al. Among authors: egging df. FEBS Open Bio. 2017 Sep 5;7(10):1557-1574. doi: 10.1002/2211-5463.12283. eCollection 2017 Oct. FEBS Open Bio. 2017. PMID: 28979843 Free PMC article.
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, Groothuis P, Beusker P, Coumans R, Elgersma R, Menge W, Joosten J, Spijker H, Huijbregts T, de Groot V, Eppink M, de Roo G, Verheijden G, Timmers M. Dokter W, et al. Mol Cancer Ther. 2014 Nov;13(11):2618-29. doi: 10.1158/1535-7163.MCT-14-0040-T. Epub 2014 Sep 4. Mol Cancer Ther. 2014. PMID: 25189543
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH. van der Lee MM, et al. Among authors: egging df. Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14. Mol Cancer Ther. 2015. PMID: 25589493
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH. Elgersma RC, et al. Among authors: egging df. Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25635711
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Ubink R, Dirksen EHC, Rouwette M, Bos ES, Janssen I, Egging DF, Loosveld EM, van Achterberg TA, Berentsen K, van der Lee MMC, Bichat F, Raguin O, van der Vleuten MAJ, Groothuis PG, Dokter WHA. Ubink R, et al. Among authors: egging df. Mol Cancer Ther. 2018 Nov;17(11):2389-2398. doi: 10.1158/1535-7163.MCT-18-0329. Epub 2018 Aug 9. Mol Cancer Ther. 2018. PMID: 30093567
19 results